BY Dawn Dorsey

A type of drug that blocks the binding of cancer-promoting proteins may be suitable for treatment-resistant non-small cell lung cancer (NSCLC), especially if a specific growth factor is activated, according to a case study published today in the Clinical Therapeutics section of The New England Journal of Medicine.

The article, written by a team of researchers while they were fellows at The University of Texas MD Anderson Cancer...